Limited coverage drugs – paliperidone palmitate

paliperidone palmitate

Invega Sustenna^®: 50 mg/0.5 mL, 75 mg/0.75 mL, 100 mg/1 mL, 150 mg/1.5 mL

Invega Trinza^®: 175 mg/0.875 mL, 263 mg/1.315 mL, 350 mg/1.75 mL, 525 mg/2.625 mL

prolonged-release injectable suspension in a pre-filled syringe

Management of the manifestations of schizophrenia or related psychotic disorders (not dementia-related) in:

1. patients who have tried oral paliperidone, aripiprazole or risperidone and at least one other antipsychotic agent
   AND
   whose condition continues to be inadequately controlled at maximally tolerated doses

OR

2. patients who are currently receiving a conventional depot antipsychotic
   AND
   are experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia.

OR

3. patients with a history of non-adherence to antipsychotic medication resulting in negative outcomes such as repeated hospitalizations

Indefinite